"Fosun International, a conglomerate based in Hong Kong and Shanghai, held an interim results presentation in Shanghai on August 29th, 2025. Guo Guangchang, Chairman, highlighted significant breakthroughs particularly in biopharmaceutical segment. The company aims to deepen industries with advantages to accelerate growth. Fosun focused on core industries, divesting non-core assets. Wang Qunbin, Co-Chairman, emphasized managing debt levels for development. Fosun prioritizes growth in biopharmaceuticals, cultural tourism, and consumption. Innovation is central to their strategy, with breakthroughs in technology highlighted. Chen Qiyu, Co-CEO, stressed innovation focus for future development. Overall, Fosun's strategy revolves around innovation and growth in core sectors." (Characters: 773)